TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04747054
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the investigator decide to add chemotherapy with pembrolizumab, and depending on the radiotherapy timing:~* Start of radiotherapy planned before 3rd cycle: Chemotherapy could be delayed after the end of radiotherapy and start from cycle 3 or 4 of pembrolizumab. Administration of chemotherapy can be delayed in case of non resolved grade 3 or higher toxicity from radiotherapy.~* Radiotherapy planned after 3rd cycle: Chemotherapy should start at the same time of pembrolizumab.~Chemotherapy will combine carboplatin AUC 5mg/mL/min or cisplatin 100mg/m² every 3 weeks with 5-FU 1000mg/m²/j during 4 days every 3 weeks for a maximum of 6 cycles
Study: NCT06045858
Drug: Anticoagulation Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: anticoagulation in peritoneal dialysis patients with non valvular atrial fibrillation during one year
Study: NCT05522582
Drug: Methotrexate tablets
Normalized name: Methotrexate Tablets
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets with 5mg methotrexate are taken orally twice a week during the whole course of radiotherapy
Study: NCT05327127
Drug: K-877-ER
Normalized name: K+ 8 MEQ Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877-ER tablet
Study: NCT05327127
Drug: CSG452
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSG452 tablet
Study: NCT05327127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT05175430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (per os) for the Paroxetine condition will be used to compare the data from the study day with LSD between both arms.
Study: NCT04801849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take a placebo vitamin E capsule daily for 24 weeks
Study: NCT05816863
Drug: pabolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: pabolizumab IV every 3 weeks (q3w)
Study: NCT06657885
Drug: his is a prospective, single-arm, multicentre, non-randomised phase II, pilot study designed to achieve or maintain virological success in participants who meet the prescribing criteria for lenacapavi
Approvals — FDA: no, EMA: no, PMDA: no
Description: cabotegravir initiation: daily oral route of 1 tablet 30 mg at Day 0 to week 4 Cabotegravir maintennace: Every 8 weeks (+/- 1 week) intramuscular injection from week 8 at week 48.~Lenacapavir initiation: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites + orale route of 2 tablets of 300mg (ie 600 mg) at Day 0 and at day 1: orale route of 2 tablets of 300mg (ie 600 mg) Lenacapavir maintenance: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites every 24 weeks (+/-1 week) from Day 0 to Week 48
Study: NCT06385795
Drug: NOE-115
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NOE-115 is an investigational monoamine modulator which has potential anti-inflammatory activity.
Study: NCT05849675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose placebo
Study: NCT04826107
Drug: DP303c treatment（second-line of HER2-positive）
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP303c injection, every 3 weeks.
Study: NCT04826107
Drug: DP303c treatment （third-line of HER2-positive）
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP303c injection, every 3 weeks.
Study: NCT04826107
Drug: DP303c treatment（≥second-line of HER2 low expressing）
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP303c injection, every 3 weeks.
Study: NCT04826107
Drug: DP303c + PD-1/PD-L1 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP303c injection + PD-1/PD-L1 injection, dose and frequency to be determined.
Study: NCT06279364
Drug: SKB264
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT06279364
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet. Oral route of administration.
Study: NCT04730635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose matched placebo capsule QD, orally for Days 1-56.
Study: NCT06372652
Drug: TE-8214 - SAD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohort 1 - Single subcutaneous dose of 0.6 mg Cohort 2- Single subcutaneous dose of 1.2 mg Cohort 3 - Single subcutaneous dose of 2.0 mg Cohort 4 - Single subcutaneous dose of 3.0 mg or 4.0 mg Cohort 5 (Optional) - Single subcutaneous dose of 6.0 mg
Study: NCT06372652
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous dose of matching placebo across the cohorts
Study: NCT05772455
Drug: XZB-0004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1a: 100mg BID, 150mg BID, and 200mg BID of XZB-0004 are planned to be evaluated, and the possibility of exploring higher or lower doses is not ruled out. Continuous administration of XZB-0004 for 21 days is a treatment cycle. Part 1b: XZB-0004 in combination with Penpulimab in subjects with advanced NSCLC or solid tumors, starting at a dose level down from the RP2D of XZB-0004 monotherapy- cohort 1: Advanced or metastatic NSCLC with advanced disease progression after treatment with PD-1 or PD-L1 inhibitors; cohort 2: Advanced or metastatic NSCLC with advanced disease progression after platinum-containing chemotherapy without prior use of any immunocheckpoint inhibitors; cohort3: Advanced or metastatic solid tumors that cannot be radically cured by surgery or local therapy, including but not limited to urothelial carcinoma, melanoma, etc. Subjects had disease progression since last antitumor therapy, no availability or intolerance or refusal of standard therapy.
Study: NCT05779241
Drug: LYN-005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone long-acting oral capsule
Study: NCT06170463
Drug: MI/DCI combination in 40:1 ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: MI-group received MI/DCI combination in 40:1 ratio twice daily
Study: NCT06388148
Drug: Medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.
Study: NCT06659653
Drug: PRG2302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose group 1: with a dosage of 0.5x10\^6 (cells/kg) per dose Dose group 2: with a dosage of 1.0x10\^6 (cells/kg) per dose Dose group 3: with a dosage of 2.0x10\^6 (cells/kg) per dose
Study: NCT06661005
Drug: IV Sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia induction will be done by an anesthesiologist with propofol per standard protocol. A pulse oximeter will be placed and oxygen will be administered through a nasal cannula and the patient will be instructed to breath.
Study: NCT05041907
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies: 300mg tixagevimab/ 300 mg cilgavimab given once on D0
Study: NCT05041907
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine 40mg OD for 7/7
Study: NCT05041907
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies: 600mg casirivimab/ 600mg imdevimab given once on D0
Study: NCT06285201
Drug: R
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/kg IV of Test drug manufactured by Patheon Italia
Study: NCT06087237
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets three times per day starting from the day before surgery till two weeks after the surgery.
Study: NCT05866679
Drug: Hyperpolarized 13-C-pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO
Study: NCT05723731
Drug: Laxative Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisacodyl or glycerin enemas can be used in patients who do not have a bowel movement for more than 3 days.
Study: NCT06209138
Drug: 5 fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 fluorouracil (5FU) using different ratios of hydroxyl propyl methyl cellulose (HPMC) and Zein
Study: NCT04597359
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06238895
Drug: Tardyferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval Dosing Strategy (Administration of oral iron every second day with double the standard dose instead of every day standard dose)
Study: NCT06019039
Drug: Normal Saline Flush
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five milliliters of sterile saline will be administered as a flush through the needle while recording the color flow doppler images. The same procedure will be repeated with a slow injection of 5 mL of saline. The speed of injection will not be standardized.
Study: NCT06115473
Drug: epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive epinephrine prepared as 10 ml syringe filled with 10 ml of epinephrine 10 mcg/ml. prepared by drawing 1ml epinephrine 1mg ampule into 9 ml saline then discarding 9 ml and adding another 9 ml saline. now the investigators have 10 ml of epinephrine 10 mcg/ ml (1:100,000), then 10 µg will be given intravenously every 2-minute starting before intubation and continue during and after intubation for 4 times or until the systolic blood pressure (SBP) will be at least 90 mmHg or the mean arterial pressure (MAP) 65 mmHg or greater or after 4th dose of epinephrine and still hypotensive vasopressor (norepinephrine 30 ng /kg/min.) will be added or increased.
Study: NCT05653310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Capsule
Study: NCT05594927
Drug: Huachansu
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg (4 x 300 mg tablets) huachansu administered orally three times a day (30 minutes after breakfast, lunch and dinner, respectively) until treatment discontinuation criteria are met.
Study: NCT06302426
Drug: INI-4001
Approvals — FDA: no, EMA: no, PMDA: no
Description: INI-4001 is a small molecule TLR7/8 agonist being developed as a standalone treatment for the induction of anti-tumour immune responses and sensitization to immune checkpoint inhibitor (ICI) therapy.
Study: NCT04961528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 5ml x 3/day (= 5 ml / 8 hours) Treatments duration: 3 days.
Study: NCT06637527
Drug: OK-101 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% Ophthalmic Solution
Study: NCT06637527
Drug: OK-101 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% Ophthalmic Solution
Study: NCT06637527
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04845659
Drug: Doptelet Pill
Normalized name: Doptelet Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg or 60 mg Doptelet orally 10-13 days before planned procedure.
Study: NCT05947461
Drug: 100mg diclofenac
Normalized name: diclofenac sodium 100 MG
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients without contraindications should receive 100mg rectal diclofenac 30mins before ERCP procedure
Study: NCT05947461
Drug: 100mg indomethacin
Normalized name: indomethacin 100 MG
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients without contraindications should receive 100mg rectal indomethacin 30mins before ERCP procedure
Study: NCT05120570
Drug: VIC- 1911
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg, 50 mg, or 75 mg administered twice a day from day 5 post HCT to day 45, and the dose escalation will stop once we identify the lowest biologically active and safe dose of VIC.
Study: NCT04683146
Drug: Hand antisepsis with Propanolol- 1 60%.
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using Propanolol-1 60% in both hands.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later
Study: NCT05389514
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive a single dose of cyclophosphamide 60 mg/kg IV in 250 ml D5W over 2 hours on Day -3.
Study: NCT05517980
Drug: KP104
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive loading and/or weekly maintenance subcutaneous (SC) doses of KP104.
Study: NCT06574126
Drug: Group 1: Dara-VRD followed by apheresis and cilta-cel infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Group 1, 10 eligible participants will undergo a maximum of two 28-day induction cycles with Dara-VRD. Participants in Group 1 are considered enrolled as the date of signing the Informed Consent Form. This will be followed by apheresis according to institutional standards with the collection target and instructions for processing and shipping apheresis product provided in the Cell Therapy Investigational Product Procedures Manual. Cilta-cel will be generated from T cells selected from the apheresis. Participants for whom apheresis or manufacturing fails will be allowed a second attempt of apheresis. Between apheresis and cilta-cel infusion, participants will be allowed to have stem cell collection using GCSF+/-plerixafor. Cilta-cel will be manufactured by transduction of T cells with an LV vector expressing anti-BCMA CAR, followed by T cell expansion.
Study: NCT06574126
Drug: Group 2: Apheresis followed by Dara-VRD and cilta-cel infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Group 2, 10 eligible participants will undergo apheresis first, according to institutional standards with the collection target and instructions for processing and shipping apheresis product provided in the Cell Therapy Investigational Product Procedures Manual. Study enrollment is defined as the date of signing Informed Consent Form. The apheresis will be followed by a maximum of two 28-day induction cycles with DARA-VRD. Cilta-cel will be generated from T cells selected from the apheresis. Participants for whom the apheresis or manufacturing fails will be allowed a second attempt at apheresis. Between apheresis and cilta-cel infusion, participants will be allowed to have stem cell collection using GCSF+/-plerixafor. Cilta-cel will be manufactured by transduction of T cells with an LV vector expressing anti-BCMA CAR, followed by T cell expansion.
Study: NCT06146751
Drug: Superparamagnetic Iron Oxide Nanoparticles
Normalized name: iron oxide, nanoparticles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a novel ferumoxytol-enhanced cardiac magnetic resonance imaging.
Study: NCT05932654
Drug: BSI-045B
Normalized name: CENTRAL LINE DRESSING ERASE BSI CHANGE KIT MEDLINE #BSIPICC1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with BSI-045B.
Study: NCT06662318
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl was given as a bolus of 1 µg/kg injected followed by a fentanyl infusion of 0.4 µg/kg/h. Fentanyl infusion was continued as Postoperative analgesia for 24 hours in a dose of 0.3 µg/kg/h.
Study: NCT05551871
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the patient will receive Simvastatin for 7 days
Study: NCT06096870
Drug: PDS01ADC
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDS01ADC at 12.0 microgram/kg by subcutaneous injection (every 28 days)
Study: NCT04878627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receive placebo for 3 weeks
Study: NCT06532071
Drug: [68Ga]CBP8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intravenous injection of up to 350 MBq of \[68Ga\]CBP8
Study: NCT06111586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion at Day 1 and SC Injection from W2 to W102
Study: NCT05075824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo will be administered with the same dosing schedule and equivalent IV and SC volume as weight-based Crovalimab.
Study: NCT04345796
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D
Study: NCT05815550
Drug: PPI
Normalized name: PPIase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of PPI defined as PPI mentioned in the safety report
Study: NCT06797674
Drug: MK-7602
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT05349721
Drug: PTC857
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTC8657 will be administered as an oral solution twice a day.
Study: NCT05349721
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as an oral solution twice a day.
Study: NCT05644665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05844618
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Day 1, Day 2, and Day 3, subjects will receive 2 applications of 3 mg/cm2 on the same lesional area, at an interval of approximately 12 ± 2 hours.
Study: NCT05280158
Drug: mRNA-1273 (Moderna COVID-19 vaccine)
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Drug will be administered via intramuscular injection (IM). Only one dose of study drug will be administered for the study.
Study: NCT06152042
Drug: BMF-219
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
Study: NCT05924165
Drug: 10mg Ketorolac, Q6 PRN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac is an NSAID used to relieve moderately severe pain.
Study: NCT06354660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05276570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: calculated volume to match active treatment by inhalation of nebulized solution
Study: NCT06072482
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06072482
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive SoC background immunosuppressive therapy for induction and maintenance, at the discretion of the Investigator and as supported by current guidelines, product labels and local practices and informed by the individual participant's clinical condition, preferences, and values.
Study: NCT06174402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet/ day
Study: NCT04681638
Drug: Pathogen-Reduced Plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment group will receive an additional infusion of Pathogen-Reduced Plasma based on the formula, hourly rate, mL/hr = (1 mL\*kg\*TBSA)/24 hr. This infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.
Study: NCT05791565
Drug: Salbutamol HFA-152a
Normalized name: HYDROFLUOROCARBON 152A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol HFA-152a will be administered.
Study: NCT05791565
Drug: Salbutamol HFA-134a
Normalized name: HYDROFLUOROCARBON 134A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol HFA-134a will be administered.
Study: NCT05081518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - capsule
Study: NCT06246110
Drug: EIK1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: EIK1001 is a Toll like receptor 7/8 (TLR 7/8) agonist
Study: NCT05464914
Drug: CEO Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: is a eugenol-free, surgical dressing and periodontal pack that has no burning sensation, no unpleasant taste or odor, and offers proven protection to surgical sites. This product promotes cleanliness and healing. Plastic and cohesive, ropes of any length or thickness can be formed. The smooth texture allows this product to adapt closely to the teeth and tissue in order to protect the wound. It sets with resilient, non-brittle hardness.
Study: NCT05620836
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, Tablet
Study: NCT06230757
Drug: Placebo (active placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg psilocybin capsule
Study: NCT06028321
Drug: Part 2 Group G (ACM-001.1)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
Study: NCT06028321
Drug: Part 1 Group 1 Regimen B (Pindolol)
Normalized name: meningococcal group B vaccine 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: pindolol tablets for oral use. Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
Study: NCT06435858
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT05034497
Drug: 186RNL
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will be required to have an Ommaya Reservoir and a CSF Flow Study.~Participants will receive a single 5cc dose of 186RNL via Ommaya Reservoir.
Study: NCT05689645
Drug: F573 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first stage:the first 16 patients with liver injury were given doses of 0.5, 1.0 and 2.0 mg/kg, and the subsequent 9 patients with CHB were given doses of 2.0 mg/kg, with an administration volume of 2 mL and intramuscular injection (IM) according to the efficacy and safety test results of the first 16 patients. The dose was given once a day for 7 days and calculated according to the weight of the last visit.~The second stage:According to the results of Phase I efficacy and safety trials, the dosage was determined to be 0.5 mg/kg and 2.0 mg/kg, the dosage volume was 2 mL, intramuscular injection (IM), once a day for 14 days, and the dosage was calculated according to the weight of the latest visit.~The third stage:The dosage was determined according to the results of the first and second phase efficacy and safety trials. The dosage volume was 2 mL, intramuscular injection (IM), once a day for 28 consecutive days, and the dosage was calculated according to the weight of the latest .